Marshall Financial Group LLC Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Marshall Financial Group LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,286 shares of the company’s stock after acquiring an additional 290 shares during the period. Marshall Financial Group LLC’s holdings in IDEXX Laboratories were worth $960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Hurley Capital LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at $29,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $30,000. Colonial Trust Co SC increased its position in shares of IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after acquiring an additional 39 shares during the last quarter. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $38,000. Finally, Itau Unibanco Holding S.A. boosted its holdings in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after purchasing an additional 81 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Stifel Nicolaus lifted their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a “hold” rating in a report on Monday, May 19th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Finally, Leerink Partners boosted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $546.00.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares of the company’s stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $526.92 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $42.38 billion, a PE ratio of 49.38, a P/E/G ratio of 3.41 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $537.00. The business’s fifty day moving average price is $469.88 and its two-hundred day moving average price is $443.57.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.71 earnings per share. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.